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Abstract
Background: The absence of a uniform and clinically relevant definition of severe postpartum haemorrhage
hampers comparative studies and optimization of clinical management. The concept of persistent postpartum
haemorrhage, based on refractoriness to initial first-line treatment, was proposed as an alternative to common
definitions that are either based on estimations of blood loss or transfused units of packed red blood cells
(RBC). We compared characteristics and outcomes of women with severe postpartum haemorrhage captured
by these three types of definitions.
Methods: In this large retrospective cohort study in 61 hospitals in the Netherlands we included 1391 consecutive
women with postpartum haemorrhage who received either ≥4 units of RBC or a multicomponent transfusion. Clinical
characteristics and outcomes of women with severe postpartum haemorrhage defined as persistent postpartum
haemorrhage were compared to definitions based on estimated blood loss or transfused units of RBC within 24 h
following birth. Adverse maternal outcome was a composite of maternal mortality, hysterectomy, arterial embolisation
and intensive care unit admission.
Results: One thousand two hundred sixty out of 1391 women (90.6%) with postpartum haemorrhage fulfilled the
definition of persistent postpartum haemorrhage. The majority, 820/1260 (65.1%), fulfilled this definition within 1 h
following birth, compared to 819/1391 (58.7%) applying the definition of ≥1 L blood loss and 37/845 (4.4%) applying
the definition of ≥4 units of RBC. The definition persistent postpartum haemorrhage captured 430/471 adverse maternal
outcomes (91.3%), compared to 471/471 (100%) for ≥1 L blood loss and 383/471 (81.3%) for ≥4 units of RBC. Persistent
postpartum haemorrhage did not capture all adverse outcomes because of missing data on timing of initial, first-line
treatment.
Conclusion: The definition persistent postpartum haemorrhage identified women with severe postpartum haemorrhage
at an early stage of haemorrhage, unlike definitions based on blood transfusion. It also captured a large majority of
adverse maternal outcomes, almost as large as the definition of ≥1 L blood loss, which is commonly applied as a
definition of postpartum haemorrhage rather than severe haemorrhage.
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Background
Postpartum haemorrhage is a common obstetric emer-
gency, complicating 3–8% of all births [1–6]. Severe
postpartum haemorrhage accounts for more than a
quarter of all maternal deaths worldwide [7], and is the
leading cause of severe maternal morbidity in high-
resource countries [4, 5, 8–10]. Consequently, prevention
and optimization of its management continue to receive
considerable attention.
Optimization of management of postpartum haemor-
rhage, however, is currently hampered by the use of
many different definitions of severe postpartum haemor-
rhage. Commonly used definitions of postpartum haem-
orrhage and its severity are based on estimations of
blood loss or the need of transfusion of packed red
blood cells (RBC) within 24 h following birth [11–19].
Severity of postpartum haemorrhage, however, depends
not only on volume, but also on the rate of blood loss,
physiological response to bleeding and response to treat-
ment [11, 20, 21]. Such characteristics of bleeding are
important determinants of clinical management during
the dynamic process of ongoing haemorrhage [20]. The
need for transfusion on the other hand, reflects an inter-
mediary state during ongoing bleeding or the end stage
of haemorrhage, and is therefore unsuitable when it
comes to decisions regarding when to start more aggres-
sive interventions to prevent adverse maternal outcome
in women with severe postpartum haemorrhage.
Because of these shortcomings, a panel of experts on
postpartum haemorrhage proposed to define severe post-
partum haemorrhage not only according to the volume of
blood loss, but also to failure to respond to initial, first-line
measures to control bleeding. An important advantage of
this definition, which they named persistent postpartum
haemorrhage [11], is that it can be universally applied in
low-, middle- and high-income settings, since the initial,
first-line uterotonic and surgical measures to stop bleeding
are commonly performed across all regions. This includes
regions dealing with lack of blood for transfusion, where
many women who suffer from severe haemorrhage would
not be included if case definitions based on the number of
transfusions given would be applied [17]. Furthermore,
‘refractoriness to treatment’ is a clear-cut moment during
haemorrhage that may allow for differentiation between
women who will stop bleeding soon, and those with on-
going haemorrhage who are at increased risk of adverse
maternal outcome.
In order to gain knowledge on the case-mix of
women captured by persistent postpartum haemorrhage
as a definition of severe postpartum haemorrhage, we
aimed to describe clinical characteristics and outcomes
of women selected by this definition, as compared to
definitions based on estimations of blood loss and
transfused RBC.
Methods
Population
The current analysis was performed as part of the
TeMpOH-1 study, a cohort study in the Netherlands on
Transfusion strategies in women with Major Obstetric
Haemorrhage in which 61 out of 86 hospitals (71%)
participated. In the TeMpOH-1 study, we included
consecutive women who, from January 1st, 2011, to
January 1st, 2013, received either ≥4 units of RBC or a
multicomponent blood transfusion within 24 h following
birth because of postpartum haemorrhage exceeding
1000mL of blood loss. A multicomponent blood transfu-
sion was defined as blood transfusion consisting of a com-
bination of RBC and fresh frozen plasma and/or platelet
concentrates. Women were retrospectively selected from
transfusion databases and birth registries of participating
hospitals.
The study was registered in the Netherlands Trial
Register (identifier NTR 4079).
Data collection
Detailed information concerning pregnancy, birth and
the course of bleeding was gathered from routinely doc-
umented medical information. Comprehensive chart re-
views were uniformly performed by well-trained medical
students and research nurses. At the end of data collec-
tion, the first author and two data managers checked all
data for completeness and inconsistencies, and whenever
necessary, on-site chart review was repeated.
Collected data included age, ethnicity, weight, height,
comorbidity, mode of birth, primary cause of haemor-
rhage, consecutive estimates of blood loss and timing of
estimations, blood pressure and heart rate throughout
the haemorrhage and timing of measurements, volume
of clear fluids for fluid resuscitation and timing of
administration, timing of all obstetric and haemostatic
interventions to control bleeding, timing of adminis-
tration of every unit of RBC, fresh frozen plasma and
platelets.
Outcomes
We followed women from onset of childbirth until ces-
sation of bleeding postpartum or death, and in this man-
ner reconstructed the course of every included woman
with postpartum haemorrhage. Primary outcome was
adverse maternal outcome, a composite of maternal
mortality and severe maternal morbidity, with the latter
defined as postpartum arterial embolisation, hysterec-
tomy or intensive care unit admission. Secondary out-
comes were total blood loss, time from birth until
cessation of bleeding or death, total number of units of
RBC transfused and time from birth till transfusion of
first unit of RBC.
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Persistent postpartum haemorrhage
Persistent postpartum haemorrhage was defined as on-
going postpartum haemorrhage of at least 1000mL within
24 h following birth, refractory to initial, first-line treat-
ment to stop bleeding [11]. Initial, first-line treatment
depended on the primary cause of postpartum haemor-
rhage. Postpartum haemorrhage caused by uterine atony,
retained placenta, genital tract trauma, placenta previa or
placental abruption was considered persistent if bleeding
continued despite uterine massage, oxytocin, misoprostol,
methylergometrine, suturing of tears, and manual removal
of placenta or placental remnants. Women with abnor-
mally invasive placenta as primary cause of postpartum
haemorrhage, a surgical cause (including uterine rupture)
or a pre-existent coagulation disorder (congenital or ac-
quired) were regarded as having persistent postpartum
haemorrhage irrespective of initial first-line treatment,
since these complex haemorrhages require a series of ob-
stetric and haemostatic measures to control bleeding.
Blood loss, bleeding rate and signs of haemorrhagic
shock at time of inclusion
In the Netherlands, volume of blood loss during postpar-
tum haemorrhage is determined by weighing gauzes,
cloths and surgical swabs and by measurements using
suction canisters. We linearly interpolated volume of
blood loss between consecutive estimations of blood loss
throughout bleeding, by using all recorded estimations
of blood loss and timing of measurements from onset
until cessation of bleeding. Cessation of bleeding was
defined as the time of the last estimation of blood loss
recorded in the medical files or the time of the last
obstetric intervention to stop bleeding. Bleeding rate was
calculated by dividing blood loss between two consecu-
tive estimations by the time interval in between. At least
one measurement of systolic blood pressure ≤ 90 mmHg
and/or a heart rate ≥ 120 beats per minute from start of
haemorrhage till time of inclusion were considered signs
of haemorrhagic shock [22].
Statistical analysis
We summarized clinical characteristics and outcomes of
women captured by the definition persistent postpartum
haemorrhage and of women captured by different cut-offs
for estimated blood loss and for transfused units of RBC
within 24 h following birth. Cut-offs used for estimations
of blood loss were: ≥1000mL, ≥1500mL, ≥2000mL and ≥
2500mL. Cut-offs for the number of transfused units of
RBC were: ≥4 units, ≥6 units, ≥8 units and ≥ 10 units.
For every one of these nine definitions, we determined
bleeding characteristics of all women who complied with
the definition of interest. Bleeding characteristics were
calculated at the time of satisfying the criteria for each
of the definitions. For example, in case of estimation of
volume of blood loss, we calculated all bleeding charac-
teristics at the moment the women’s blood loss reached
the predefined cut-off value. Bleeding characteristics in-
cluded time from birth to time of inclusion (< 1 h, ≥1 to
2 h, ≥2 h), cause of haemorrhage (uterine atony/retained
placenta/abnormally invasive placenta/placenta previa/
placental abruption/surgical cause/pre-existent coagula-
tion disorder), volume of blood loss at moment of inclu-
sion (< 1 L, ≥1 to 2 L, ≥2 L), bleeding rate at moment of
inclusion (< 1 L/h, ≥1 to 2 L/h, ≥2 L/h), signs of haemor-
rhagic shock at moment of inclusion (no/yes), and units
of transfused RBC at moment of satisfying the criteria
for the definition (no/yes).
We also determined the occurrence of adverse maternal
outcome for women captured by all definitions of severe
postpartum haemorrhage. Lastly, we calculated for all def-
initions median blood loss, time from birth till end of
bleeding, median number of transfused units of RBC and
time from birth until transfusion of first unit of RBC.
Results
A total of 1391 women with postpartum haemorrhage out
of 270,101 births met the TeMpOH-1 inclusion criteria (5.1
per 1000 births). Persistent postpartum haemorrhage was
observed in 1260 women (90.6%) (Fig. 1). A total of 1344
out of 1391 women (96.6%) reached a minimal volume of
blood loss of 1500mL following birth, 1252 (90.0%) ≥2000
mL and 1050 (75.5%) ≥2500mL of blood loss within 24 h
following birth (Fig. 1). At least 4 units of RBC were trans-
fused within 24 h following birth in 845/1391 women
(60.7%), ≥6 units in 325/1391 women (23.4%), ≥8 units in
176/1391 women (12.7%) and ≥ 10 units in 115/1391
women (8.3%). Please note that women who received six
or more units of RBC also met the criteria for inclusion in
the previous category (≥4 units of RBC), and so on.
Time from birth to moment of meeting the criteria for
persistent postpartum haemorrhage was less than 1 h in
820 out of 1260 women (65.1%). At the moment of
meeting these criteria, 673 women (53.4%) had bled less
than 1 L (Tables 1 and 2). When defining severe post-
partum haemorrhage based on estimated blood loss,
time from birth to the moment she reached 1 L of blood
loss was less than 1 h in 819 out of 1391 women
(58.7%). With the number of transfused units of RBC
within 24 h following birth as definition, time from birth
to moment of transfusion of 4 units of RBC was less
than 1 h in 37 out of 845 women (4.4%).
Mode of birth for women meeting the criteria for
persistent postpartum haemorrhage was vaginal in
967 out of 1260 women (76.7%), comparable to women
captured by all definitions based on estimated blood loss
and transfusion of RBC up to a minimum of 4 units. A
total of 62 out of 126 women (49.2%) captured by the def-
inition ≥10 units of RBC had a vaginal birth. Cause of
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haemorrhage showed similar distributions for women cat-
egorized according to all definitions, with uterine atony
as main cause of haemorrhage. With definitions based
on the number of units transfused RBC within 24 h
following birth the proportion of abnormally invasive
placenta, surgical causes and congenital or acquired
coagulation disorders increased slightly with increasing
number of transfused units.
Adverse maternal outcome occurred in 471 out of 1391
women (33.9%) in our study. In the 1260 women meeting
the criteria for persistent postpartum haemorrhage we ob-
served 430 of these 471 women with adverse outcome
(91.3%). The 41 women with adverse maternal outcome
not captured by the definition persistent postpartum
haemorrhage all had missing data on timing of initial first-
line measures to stop bleeding, and therefore could not be
classified as having had persistent postpartum haemor-
rhage or not. Because of this, nine women with hysterec-
tomies and eight with arterial embolisations were ‘missed’
with this definition (Table 3).
The definition ≥1 L of blood loss within 24 h following
birth captured all 471 adverse outcomes and in women
with ≥2.5 L blood loss 417 of these 471 outcomes
(88.5%) were captured. One woman who was not captured
by the latter definition died. She had postpartum haemor-
rhage with blood loss of 1.5 L due to uterine atony, but
also suffered from cerebral haemorrhage as a result of
eclampsia. Two women with hysterectomies (1x abnor-
mally invasive placenta and 1x uterine atony) and five with
embolisations (4x uterine atony and 1x surgical cause)
were not captured by the definition of ≥2.5 L blood loss
within 24 h following birth, partly because of uncertain
total blood loss after postpartum haemorrhage.
A total of 383 out of 471 adverse outcomes (81.3%)
were captured by the definition transfusion of ≥4 units
of RBC within 24 h following birth and 113 out of 471
adverse outcomes (24.0%) in women with ≥10 units of
RBC transfused. Among the 88 women with adverse
outcome not captured by the definition ≥4 units of RBC
within 24 h following birth were five women with
Fig. 1 Number of women meeting the criteria for persistent postpartum haemorrhage as definition of severe postpartum haemorrhage, and
women captured by definitions of severe postpartum haemorrhage based on estimated blood loss and number of transfused units of packed red
blood cells within 24 h following birth. * A multicomponent blood transfusion was defined as blood transfusion consisting of a combination of
RBC and fresh frozen plasma and/or platelet concentrates. ‡ Women who bled ≥1500 ml also fulfilled the definition ≥1000 ml and were also
included in this previous category, and so on. Similarly, women who received ≥6 units of RBC also met the criteria for inclusion in the previous
category (≥4 units of RBC), etc
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hysterectomies (4x abnormally invasive placenta and 1x
placenta praevia) and 14 with arterial embolisations (1x
abnormally invasive placenta and 1x surgical cause).
Median total blood loss was 3.0 L (interquartile range,
IQR 2.5–4.0) in women with persistent postpartum
haemorrhage, similar to women with up to 2000mL of
blood loss at moment of inclusion (Table 4). Women
with ≥2500mL had median blood loss of 3.5 L (IQR
3.0–4.2). Number of transfused RBCs did not differ
between definition persistent postpartum haemorrhage
and all definitions based on estimated blood loss.
With increasing units of RBC transfused median total
blood loss increased from 3.4 L (IQR 2.5–4.5) to 7.0 L
(IQR 5.3–9.1) and median units transfused increased
from 5 (IQR 4–7) to 13 (IQR 11–17).
Discussion
Main findings
A large proportion of women who fulfilled the definition
persistent postpartum haemorrhage was captured at an
early stage of haemorrhage (within 1 h after birth), and
this definition captured a high proportion of adverse
maternal outcomes (91.3%). Women with this definition
for severe postpartum haemorrhage had similar clinical
characteristics and maternal outcomes compared to
women who fulfilled the definition of severe postpartum
haemorrhage up to 2000mL of blood loss.
Strengths and limitations
To the best of our knowledge, this is the first study in a
large, consecutive cohort of women with postpartum
Table 1 Bleeding characteristics at time of inclusion of women with persistent postpartum haemorrhage, as compared with women
with different cut-off values for estimations of blood loss within 24 h following birth. Women with higher volumes of blood loss are
included in the cohorts starting with lower volumes of blood loss
Bleeding characteristic Persistent postpartum
haemorrhage (N = 1260)
Blood loss ≥1000mL
(N = 1391)
Blood loss ≥1500 mL
(N = 1344)
Blood loss ≥2000mL
(N = 1252)
Blood loss ≥2500 mL
(N = 1050)
Time from birth till inclusion of patients – no. (%)
< 1 h 820 (65.1) 819 (58.7) 553 (41.1) 309 (24.7) 160 (15.2)
≥ 1–2 h 251 (19.9) 318 (22.9) 385 (28.6) 419 (33.5) 341 (32.5)
≥ 2 h 189 (15.0) 257 (18.5) 406 (30.2) 524 (41.9) 549 (52.3)
Mode of birth - no. (%)
Vaginal 967 (76.7) 1032 (74.2) 1002 (74.6) 945 (75.5) 792 (75.4)
Caesarean 285 (22.6) 351 (25.2) 3354 (24.9) 301 (24.0) 253 (24.1)
Unknown 8 (0.6) 8 (0.6) 7 (0.5) 6 (0.5) 5 (0.5)
Cause of haemorrhage – no. (%)
Uterine atony 805 (63.9) 901 (64.8) 874 (65.0) 824 (65.8) 685 (65.2)
Retained placenta 219 (17.4) 231 (16.6) 227 (16.9) 207 (16.5) 172 (16.4)
Abnormally invasive placenta 113 (9.0) 113 (8.1) 107 (8.0) 100 (8.0) 89 (8.5)
Placenta previa 12 (1.0) 19 (1.4) 19 (1.4) 18 (1.4) 17 (1.6)
Placental abruption 12 (1.0) 28 (2.0) 24 (1.8) 18 (1.4) 16 (1.5)
Surgical cause 92 (7.3) 92 (6.6) 87 (6.5) 81 (6.5) 69 (6.6)
Pre-existent coagulation
disorder
7 (0.6) 7 (0.5) 6 (0.4) 4 (0.3) 2 (0.2)
Bleeding rate – no. (%)
< 1 L/hr. 457 (36.3) 496 (35.7) 508 (37.8) 499 (39.9) 432 (41.1)
≥ 1-2 L/hr. 316 (25.1) 332 (23.9) 315 (23.4) 302 (24.1) 266 (25.3)
≥ 2 L/hr. 481 (38.2) 552 (39.7) 513 (38.2) 445 (35.5) 349 (33.2)
Unknown 6 (0.5) 11 (0.8) 8 (0.6) 6 (0.5) 3 (0.3)
Signs of haemorrhagic shock – no. (%)
No 344 (27.3) 416 (29.9) 385 (28.6) 295 (23.6) 190 (18.1)
Yes 580 (46.0) 488 (35.1) 693 (51.6) 811 (64.8) 782 (74.5)
Unknown 336 (26.7) 487 (35.0) 266 (19.8) 146 (11.7) 78 (7.4)
Packed red blood cells transfused – no. (%)
No 1196 (94.9) 1271 (91.4) 1145 (85.2) 888 (70.9) 536 (51.0)
Yes 64 (5.1) 120 (8.6) 199 (14.8) 364 (29.1) 514 (49.0)
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haemorrhage that compared clinical characteristics and
outcomes of women captured by different definitions of
severe postpartum haemorrhage. Data were collected
retrospectively, and we were able to reconstruct the
course of every woman with postpartum haemorrhage
without loss to follow-up. Previously, many authors
discussed the use of different definitions, and experts
proposed various new or adapted definitions of severe
postpartum haemorrhage [11, 14, 15, 19, 21, 23, 24].
This study provides insight into variations in bleeding
characteristics and maternal outcomes depending on the
definition used.
However, our study population comprised only women
with postpartum haemorrhage who received 4 or more
units of RBC or a multicomponent blood transfusion
within 24 h following birth, and our results cannot be gen-
eralized to all women who satisfy the criteria for persistent
postpartum haemorrhage. The effects on clinical practice
of extending the definition of severe postpartum haemor-
rhage with ‘refractoriness to treatment’ will need to be ad-
dressed in studies among all women meeting the criteria
of persistent postpartum haemorrhage. In the updated ver-
sion of the French guideline on postpartum haemorrhage,
the definition persistent postpartum haemorrhage and
Table 2 Bleeding characteristics at time of inclusion of women with persistent postpartum haemorrhage, as compared with women
with different cut-off values for transfused units of packed red blood cells (RBC) within 24 h following birth. Women with higher
numbers of RBCs are included in cohorts of women with fewer units transfused
Bleeding characteristic Persistent postpartum
haemorrhage (N = 1260)
≥4 units RBC
(N = 845)
≥6 units RBC
(N = 325)
≥8 units RBC
(N = 176)
≥10 units RBC
(N = 115)
Time from birth till inclusion of patients – no. (%)
< 1 h 820 (65.1) 37 (4.4) 9 (2.8) 4 (2.3) 2 (1.7)
≥ 1–2 h 251 (19.9) 96 (11.4) 41 (12.6) 11 (6.3) 3 (2.6)
≥ 2 h 189 (15.0) 712 (84.3) 275 (84.6) 161 (91.5) 110 (95.7)
Unknown – – – 1 (0.5) –
Mode of birth - no. (%)
Vaginal 967 (76.7) 612 (72.4) 207 (63.7) 100 (56.8) 62 (53.9)
Caesarean 285 (22.6) 228 (27.0) 116 (35.7) 75 (42.6) 53 (46.1)
Unknown 8 (0.6) 5 (0.6) 2 (0.6) 1 (0.6) –
Cause of haemorrhage – no. (%)
Uterine atony 805 (63.9) 539 (63.8) 214 (65.8) 107 (60.8) 66 (57.4)
Retained placenta 219 (17.4) 135 (16.0) 29 (8.9) 18 (10.2) 13 (11.3)
Abnormally invasive placenta 113 (9.0) 71 (8.4) 26 (8.0) 17 (9.7) 13 (11.3)
Placenta previa 12 (1.0) 13 (1.5) 6 (1.8) 4 (2.3) 3 (2.6)
Placental abruption 12 (1.0) 18 (2.1) 11 (3.4) 5 (2.8) 1 (0.9)
Surgical cause 92 (7.3) 66 (7.8) 36 (11.1) 22 (12.5) 16 (13.9)
Pre-existent coagulation disorder 7 (0.6) 3 (0.4) 3 (0.9) 3 (1.7) 3 (2.6)
Blood loss – no. (%)
< 1 L 673 (53.4) 7 (0.8) 1 (0.3) 1 (0.6) –
≥ 1-2 L 407 (32.3) 82 (9.7) 15 (4.6) 3 (1.7) 2 (1.7)
≥ 2 L 180 (14.3) 756 (89.5) 309 (95.1) 172 (97.7) 113 (98.3)
Bleeding rate – no. (%)
< 1 L/hr. 457 (36.3) 689 (81.5) 24 (74.2) 127 (72.2) 80 (69.6)
≥ 1-2 L/hr. 316 (25.1) 100 (11.8) 56 (17.2) 34 (19.3) 21 (18.3)
≥ 2 L/hr. 481 (38.2) 41 (4.9) 23 (7.1) 12 (6.8) 12 (10.4)
Unknown 6 (0.5) 15 (1.8) 5 (1.5) 3 (1.7) 2 (1.7)
Signs of haemorrhagic shock – no. (%)
No 344 (27.3) 85 (10.1) 23 (7.1) 9 (5.1) 6 (5.2)
Yes 580 (46.0) 722 (85.4) 288 (88.6) 159 (90.3) 104 (90.4)
Unknown 336 (26.7) 38 (4.5) 14 (4.3) 8 (4.5) 5 (4.3)
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failure of initial first-line management has been incorpo-
rated [25]. This guideline provides an opportunity to
further analyse the consequences of implementing this
definition in practice.
Another limitation are the 131 women (9.4%) women
in our cohort with missing information regarding the
exact time at which the initial first-line measure to stop
bleeding was employed. This excluded the possibility of
classifying all women according to the criteria for per-
sistent postpartum haemorrhage, and consequently, 41
women (8.7%) with adverse maternal outcome had to be
excluded. In daily clinical practice, these women would
have been classified correctly by using this definition, as
in daily clinical practice physicians will always have this
information at their disposal.
Interpretation
One of the most striking findings of our study is that the
use of the definition persistent postpartum haemorrhage
seems to allow for early identification of women with severe
bleeding and therefore early identification of women at risk
of adverse maternal outcome. Recent studies on timing of
interventions in women with postpartum haemorrhage have
shown improvements in maternal outcome with early start
of treatment [26, 27]. Early identification of women with
high risk of adverse maternal outcome would facilitate this,
Table 3 Adverse maternal outcome in women with persistent postpartum haemorrhage, compared with women with different cut-
off values for estimations of blood loss and transfused packed red blood cells within 24 h following birth
Definition based on Maternal death Hysterectomy Arterial embolisation Admission on intensive
care unit
Composite adverse
maternal outcome
Number of patients (%)
Persistent postpartum haemorrhage
(N = 1260)
7 (0.6) 64 (5.1) 165 (13.1) 362 (28.7) 430 (34.1)
Estimated blood loss
≥ 1000 mL (N = 1391) 7 (0.5) 73 (5.2) 173 (12.4) 399 (28.7) 471 (33.9)
≥ 1500 mL (N = 1344) 7 (0.5) 73 (5.4) 171 (12.7) 388 (28.9) 459 (34.2)
≥ 2000 mL (N = 1252) 6 (0.5) 73 (5.8) 171 (13.7) 372 (29.7) 443 (35.4)
≥ 2500 mL (N = 1050) 6 (0.6) 71 (6.8) 168 (16.0) 348 (33.1) 417 (39.7)
Transfusion of packed red blood cells
≥ 4 units (N = 845) 7 (0.8) 68 (8.0) 159 (18.8) 321 (38.0) 383 (45.3)
≥ 6 units (N = 325) 5 (1.5) 62 (19.1) 125 (38.5) 215 (66.2) 258 (79.4)
≥ 8 units (N = 176) 4 (2.3) 54 (30.7) 84 (47.7) 146 (83.0) 165 (93.8)
≥ 10 units (N = 115) 3 (2.6) 44 (38.3) 64 (55.7) 101 (87.8) 113 (98.3)
Table 4 Total blood loss and total units of transfused packed red blood cells in women with persistent postpartum haemorrhage,
compared with women with different cut-off values for estimations of blood loss and transfused packed red blood cells (RBC) within
24 h following birth
Definition based on Total blood loss (L) Time from birth till end
of bleeding (hours)
Total units of
transfused RBCs
Time from birth till transfusion
of first RBC-unit (hours)
Median (interquartile range)
Persistent postpartum haemorrhage (N = 1260) 3.0 (2.5–4.0) 3.4 (2.1–5.9) 4 (3–6) 2.5 (1.6–4.2)
Estimated blood loss
≥ 1000 mL (N = 1391) 3.0 (2.5–4.0) 3.3 (2.0–5.8) 4 (3–6) 2.5 (1.5–4.2)
≥ 1500 mL (N = 1344) 3.0 (2.5–4.0) 3.3 (2.0–5.8) 4 (3–6) 2.5 (1.5–4.2)
≥ 2000 mL (N = 1252) 3.0 (2.5–4.0) 3.4 (2.1–5.9) 4 (3–6) 2.4 (1.5–4.1)
≥ 2500 mL (N = 1050) 3.5 (3.0–4.2) 3.6 (2.1–6.1) 4 (3–6) 2.3 (1.5–3.8)
Transfusion of packed red blood cells
≥ 4 units (N = 845) 3.5 (2.7–4.5) 3.8 (2.2–6.4) 5 (4–7) 2.3 (1.4–3.7)
≥ 6 units (N = 325) 4.8 (3.6–6.5) 6.5 (3.1–8.6) 8 (6–12) 2.0 (1.0–3.3)
≥ 8 units (N = 176) 6.0 (4.5–8.0) 6.1 (4.1–12.0) 11 (9–15) 1.9 (0.8–3.3)
≥ 10 units (N = 115) 7.0 (5.1–9.8) 6.9 (4.4–12.8) 13 (11–18) 1.8 (0.7–3.0)
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ultimately leading to a reduction in severe maternal morbid-
ity and mortality. The fact that the definition persistent post-
partum haemorrhage allows for earlier inclusion is an
advantage over definitions based on estimated blood loss,
since early inclusion would also allow for more robust pro-
spective data collection during the course of haemorrhage.
The definition persistent postpartum haemorrhage
captured more than 90% women with adverse maternal
outcome because of severe postpartum haemorrhage.
This proportion was comparable to the proportions of
the definitions based on estimated blood loss within 24 h
following birth. Definitions based on transfusions of
RBC yielded a selection of women with exceptionally
high rates of adverse maternal outcome. However, the
definition ≥4 units of RBC within 24 h following birth
excluded 88 women (18.7%) with adverse maternal out-
come, considerably higher than with the definition per-
sistent postpartum haemorrhage and all definitions based
on estimated blood loss. An explanation for this finding
would be that a proportion of women with severe post-
partum haemorrhage will undergo invasive procedures
to stop bleeding before they may have reached four or
more units of RBC transfused. This survival bias was
previously also encountered in studies on massive trans-
fusion in non-pregnant patients with major haemorrhage
after trauma [28, 29]. The fact that for all women with
adverse outcomes missed by the definition, data essential
for classification were absent from the medical records,
underlines the requirement for adequate record keeping
that the definition persistent postpartum haemorrhage
needs. Implementing this definition may in this way con-
tribute to improved documentation.
An observational study among pregnant and non-
pregnant patients with massive transfusion because of
major haemorrhage of different aetiologies also concluded
that definitions of major haemorrhage based on massive
transfusion are prone to exclude a substantial proportion
of critically bleeding patients. The definition transfusion
of ≥5 units of RBC within a 4-h period excluded 77 out of
542 patients (14.2%) with major haemorrhage [30].
The experts in a recent Delphi process led by the
International Network of Obstetric Survey Systems
needed seven rounds to reach consensus on a definition
of severe postpartum haemorrhage, reaching a rate of
agreement of 75% [19]. This underlines the fact that it is
rather challenging to accommodate the variety in opin-
ion into one definition, and at the same time the need to
explore new definitions or adaptations to existing defini-
tions of severe postpartum haemorrhage [11, 14, 15, 20,
21]. The definition persistent postpartum haemorrhage is
internationally applicable and relies on basic interven-
tions to control postpartum haemorrhage [11, 17]. How-
ever, before its implementation as the standard to
identify severe haemorrhage in clinical practice, audit,
surveillance and research we will need to validate and
test this definition also in other cohorts and different
settings.
Conclusion
The definition persistent postpartum haemorrhage identi-
fied women with severe postpartum haemorrhage at an
early stage of haemorrhage and captured a large proportion
of adverse maternal outcomes. Clinical characteristics and
outcomes of women included in this definition were com-
parable to those of women selected by definitions based on
estimated blood loss up to 2 L within 24 h following birth,
but not to definitions based on the number of units of RBC
transfused. Whether or not extending the definition of se-
vere postpartum haemorrhage with ‘refractoriness to treat-
ment’ will lead to early identification of women at high risk
of adverse outcome, early start of treatment and improve-
ment of outcomes needs to be clarified in future studies.
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